Policy | June 26, 2024
CCRAS hosts national consultative meet on traditional medicine
Signs MoUs with Shri Krishna Ayush University and Dabur India
Signs MoUs with Shri Krishna Ayush University and Dabur India
Approval based on FLAURA2 results which showed Tagrisso plus chemotherapy extended median progression-free survival by nearly 9 months vs. standard of care
Ascentage Pharma announces confidential submission of draft registration statement for proposed IPO
The consultative meet, a first of its kind, will bring together representatives from diverse domains of Traditional Medicine (TM) in India
Approval based on CAPItello-291 results which showed this combination reduced the risk of disease progression or death by 50% vs. Faslodex alone in a biomarker-altered population
Second FDA approval for KRAZATI - reinforcing its potential across tumor types
Zealand Pharma anticipates initiation of a Phase 2b clinical trial in H2 2024
DSP-5336, an Investigational Menin and Mixed-lineage Leukemia Inhibitor, is Being Evaluated in Patients with Relapsed or Refractory Acute Leukemia
Ascentage Pharma has executed an Exclusive Option to License Global Rights to Olverembatinib worldwide other than China and a few other areas
The USFDA has issued 15 observations pursuant to the completion of audit. JHSGP will submit an action plan on the observations
Subscribe To Our Newsletter & Stay Updated
